Description
An adenosine A2A and A2B receptor dual antagonist; inhibits the ability of adenosine to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro; reduces tumor growth in an AT3-OVA syngeneic mouse model alone or in combination with doxorubicin; acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model